AbCellera Biologics Inc. (ABCL) vs Dianthus Therapeutics, Inc. (DNTH)
A side-by-side comparison of AbCellera Biologics Inc. and Dianthus Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ABCL
AbCellera Biologics Inc.
$13.79HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
DNTH
Dianthus Therapeutics, Inc.
$85.82HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — ABCL vs DNTH
growth of $100 · dividends reinvested · last 6yABCL -76.6% (-21.5%/yr)DNTH -23.8% (-4.4%/yr)DNTH compounded faster over this window
ABCL DNTH
ABCL vs DNTH: by the numbers
- •DNTH is the larger company ($4.80B vs $4.21B market cap).
- •Both run net losses; ABCL's is the smaller (-248.83% vs -1570.85% net margin).
Metrics side by side
Valuation
| Metric | ABCL | DNTH |
|---|---|---|
| P/S ratio | 63.64 | 2521.16 |
| P/B ratio | 4.70 | 4.10 |
Profitability
| Metric | ABCL | DNTH |
|---|---|---|
| Gross margin | 61.64% | 96.01% |
| Operating margin | -288.98% | -8739.34% |
| Net margin | -248.83% | -1570.85% |
| ROE | -18.38% | -2.55% |
| ROIC | -17.95% | -18.48% |
Growth (annualized)
| Metric | ABCL | DNTH |
|---|---|---|
| Revenue CAGR (5Y) | -31.78% | N/A |
| Total return CAGR (5Y) | -3.57% | -5.50% |
Frequently asked
- How have ABCL and DNTH total returns compared?
- Over the past 5 years, ABCL delivered -3.57% and DNTH delivered -5.50% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.